CrkL pY207 Antibody, anti-human, REAfinity™
Synonyms: Crk-like
RECOMBINANT
Clone:
REA500 | K30-391.50.80
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CrkL pY207 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
FITC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-107-704, 130-107-739
Description:
Human K-562 cells were either left untreated (right peak) or treated with 25 µM Imatinib for 2 hours at 37 °C. Cells were then fixed and permeabilized using the Cell Signaling Buffer Set A followed by intracellular staining with Anti-CrkL pY207 antibodies. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for CrkL pY207 Antibody, anti-human, REAfinity™
Overview

Clone REA500 recognizes the human CrkL antigen phosphorylated at tyrosine 207 (pY207). CRKL is a member of adaptor proteins that participate in signal transduction in response to both extracellular and intracellular stimuli, such as growth factors, cytokines, and the oncogenic BCR-ABL fusion protein. CRKL consists of an N-terminal Src homology 2 (SH2) domain followed by two SH3 domains (SH2-SH3N-SH3C). The SH2 domain of CRKL binds to phosphorylated Y-x-x-P motif present in many docking proteins, such as BCAR1, Paxillin, and GAB, whereas the SH3N domain binds to proline-rich P-x-x-P-x-K motif-containing proteins, such as Son of Sevenless (SOS), RAPGEF1, p85, ABL1, and BCR-ABL. Through these interactions, CRKL facilitates the timely and localized formation of protein complexes required for signal transduction in many biological processes including cell proliferation, survival, adhesion, and migration. CRKL is preferentially expressed in hematopoietic cells. Y207 in CRKL represents the major in vivo phosphorylation site. It is phosphorylated in hematopoietic cells that express the BCR-ABL fusion protein. Phosphorylation of Y207 provides a binding site for the CRKL SH2 domain and potentially for other SH2-containing proteins.

Additional information: Clone REA500 displays negligible binding to Fc receptors.

Alternative names

Crk-like

Detailed product information

Technical specifications

Clone
REA500
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CrkL pY207
Molecular mass of antigen [kDa]
34
Entrez Gene ID
RRID
AB_2651460, AB_2651459, AB_2651461, AB_2651462, AB_2651458, AB_2651457

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CrkL pY207 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CrkL pY207 Antibody, anti-human, REAfinity™
Publications
  1. de Jong, R. et al. (1997) Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 14 (5): 507-513
  2. Park, T. J. et al. (2014) Essential roles of Crk and CrkL in fibroblast structure and motility. Oncogene 33 (43): 5121-5132
  3. ten Hoeve, J. et al. (2002) Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 16: 5662-5668

You have previously chosen International as your location.
What do you want to do?